EGFR L861Q | Cancer Search

mutation class

Small Mutation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

343 sites for NCT04181060

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

bevacizumab, +1 more drug

targeted therapy

Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

61 sites for NCT03318939

EGFR A763_Y764insFQEA, +31 more biomarkers

Non-Small Cell Lung Carcinoma

poziotinib

targeted therapy

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

81 sites for NCT02609776

EGFR A763_Y764insFQEA, +19 more biomarkers

Lung Adenocarcinoma, +2 more conditions

amivantamab, +3 more drugs

chemotherapy, +1 more type

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

151 sites for NCT03940703

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

osimertinib, +1 more drug

targeted therapy

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

10 sites for NCT04816214

EGFR A763_Y764insFQEA, +7 more biomarkers

Non-Small Cell Lung Carcinoma

capmatinib, +1 more drug

targeted therapy

Show 42 Trials for EGFR L861Q

afatinib

EGFR Codon 719 Missense, +4 more biomarkers

Non-Small Cell Lung Carcinoma